Cancer research aims to target and eliminate cancer cells. Senescent cells, which stop replicating and attract the immune system, are a crucial focus in cancer research. Destroying cancer can leave behind senescent cells, impacting the patient’s health. Senolytics, drugs that target senescent cells, show promise in improving cancer treatments. The role of senescent cells in cancer progression and treatment is complex and remains a topic of debate.
The article, “Therapy-Induced Cellular Senescence: Potentiating Tumor Elimination or Driving Cancer Resistance and Recurrence?” delves into the dual nature of senescent cells in cancer. While senescence can act as a barrier against cancer, it can also drive cancer progression and resistance to therapy. Studies show that eliminating senescent cells can delay tumorigenesis and improve cancer outcomes. However, therapy-induced senescence may also trigger an immune response that inhibits tumor growth.
The review on cellular senescence explores the complex interplay between senescent cells and the immune system in the tumor microenvironment. It discusses the potential of senolytics to modulate the negative effects of senescence and enhance its positive impact on cancer therapy. Understanding the Jekyll and Hyde nature of senescent cancer cells is essential for developing more effective treatments for cancer.
